Mexico - Delayed Quote MXN

bluebird bio, Inc. (BLUE.MX)

80.00

0.00

(0.00%)

As of April 21 at 7:41:33 AM CST. Market Open.

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

SOMERVILLE, Mass., May 16, 2025--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird"), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated instructions for stockholders to tender their shares into the offer.

Business Wire 3 days ago

BLUE

CG
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

SOMERVILLE, Mass., May 14, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird"), Carlyle (NASDAQ: CG) ("Carlyle") and SK Capital Partners, LP ("SK Capital") today announced they have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right ("CVR") of $6

Business Wire 6 days ago

CG

BLUE
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

SOMERVILLE, Mass., May 09, 2025--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025.

Business Wire 11 days ago

BLUE
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

SOMERVILLE, Mass., May 05, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company"), Carlyle (NASDAQ: CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") announced today that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received.

Business Wire 14 days ago

BLUE

CG
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

SOMERVILLE, Mass., April 16, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. ("Ayrmid") has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the "Board") reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and r

Business Wire last month

BLUE
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

SOMERVILLE, Mass., March 28, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone.

Business Wire last month

BLUE
Gene therapy maker bluebird to go private in discounted deal amid cash crunch

(Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital Partners at a discount, after a prolonged struggle to survive a cash crunch due to a difficult market environment for gene therapies. The company first raised going concern doubts three years ago and laid off a quarter of its workforce last year to focus on launching its three gene therapies, including Lyfgenia for sickle cell disease, which has seen slow uptake, partly due to a lengthy treatment process. The go-private deal will now provide the "primary capital" required to scale bluebird's commercialization efforts for gene therapies.

Reuters 2 months ago

BLUE
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP ("SK Capital") in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will provide bluebird pri

Business Wire 2 months ago

CG

BLUE
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat […]

Insider Monkey 4 months ago

BLUE
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERVILLE, Mass., December 08, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation on Sunday, December 8 at 9:30 a.m. Pacific Time and a poster presentation on Sunday, December 8 at 6

Business Wire 5 months ago

BLUE
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

SOMERVILLE, Mass., December 07, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.

Business Wire 5 months ago

BLUE
bluebird bio Announces 1-for-20 Reverse Stock Split

SOMERVILLE, Mass., December 04, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock Split") of the Company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primary goal of the Reverse Stock Split is to increase the per share market price of the Company’s common s

Business Wire 5 months ago

BLUE
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

SOMERVILLE, Mass., December 04, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs).

Business Wire 5 months ago

BLUE
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

bluebird bio ( NASDAQ:BLUE ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.6m (down 14% from 3Q...

Simply Wall St. 5 months ago

BLUE
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress.

Business Wire 6 months ago

BLUE
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

SOMERVILLE, Mass., November 06, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The

Business Wire 6 months ago

BLUE
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERVILLE, Mass., November 05, 2024--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition

Business Wire 6 months ago

BLUE
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical industry remains a hub of […]

Insider Monkey 6 months ago

BLUE
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy

Newly released data reveals that seven out of 67 children treated with Bluebird Bio Inc's (NASDAQ:BLUE) gene therapy for a severe neurological disorder in clinical trials have developed blood cancers. This marks an increase of four cases since June 2022, when the emergence of three cancer cases led the FDA to convene an advisory panel before approving the therapy, now marketed as Skysona. The STAT News report noted that one child passed away due to complications from cancer treatment. Also Read:

Benzinga 7 months ago

BLUE
Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and Skysona.

Pharmaceutical Technology 7 months ago

BLUE

Performance Overview

Return	BLUE.MX	S&P 500 (^GSPC)
YTD	-57.21%	+0.80%
1-Year	-77.27%	+11.69%
3-Year	-95.18%	+51.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

bluebird bio, Inc. (BLUE.MX)

Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions

Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement

Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Gene therapy maker bluebird to go private in discounted deal amid cash crunch

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

bluebird bio Announces 1-for-20 Reverse Stock Split

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies

Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy

Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials

Performance Overview